Pietro Mascheroni

Pietro Mascheroni

Auto-generated profile, based on publicly available information

Pietro Mascheroni

Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Communications Medicine
Verified
Journal Article
Open access
PDF file
PMPietro Mascheroni
Pietro Mascheroni
Symeon SavvopoulosSymeon Savvopoulos
Symeon Savvopoulos
JAJuan Carlos López Alfonso
Juan Carlos López Alfonso
MMMichael Meyer-Hermann
Michael Meyer-Hermann
Haralampos HatzikirouHaralampos Hatzikirou
Haralampos Hatzikirou
Background: In clinical practice, a plethora of medical examinations are conducted to assess the state of a patient’s pathology producing a variety of clinical data. However, investigation of these data faces two major challenges. Firstly, we lack the knowledge of the mechanisms involved in regulating these data variables, and secondly, data collection is sparse in time since it relies on patient’s clinical presentation. The former limits the predictive accuracy of clinical outcomes for any mechanistic model. The latter restrains any machine learning algorithm to accurately infer the corresponding disease dynamics.Methods: Here, we propose a novel method, based on the Bayesian coupling of mathematical modeling and machine learning, aiming at improving individualized predictions by addressing the aforementioned challenges.Results: We evaluate the proposed method on a synthetic dataset for brain tumor growth and analyze its performance in predicting two relevant clinical outputs. The method results in improved predictions in almost all simulated patients, especially for those with a late clinical presentation (>95% patients show improvements compared to standard mathematical modeling). In addition, we test the methodology in two additional settings dealing with real patient cohorts. In both cases, namely cancer growth in chronic lymphocytic leukemia and ovarian cancer, predictions show excellent agreement with reported clinical outcomes (around 60% reduction of mean squared error).Conclusions: We show that the combination of machine learning and mathematical modeling approaches can lead to accurate predictions of clinical outputs in the context of data sparsity and limited knowledge of disease mechanisms.

18 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
IRIlaria Rizzuti
Ilaria Rizzuti
PMPietro Mascheroni
Pietro Mascheroni
SASilvia Arcucci
Silvia Arcucci
ZBZacchari Ben-Mériem
Zacchari Ben-Mériem
APAudrey Prunet
Audrey Prunet
MDMorgan Delarue
Morgan Delarue
While many cellular mechanisms leading to chemotherapeutic resistance have been identified, there is an increasing realization that tumor-stroma interactions also play an important role. In particular, mechanical alterations are inherent to solid cancer progression and profoundly impact cell physiology. Here, we explore the impact of compressive stress on the efficacy of chemotherapeutics in pancreatic cancer spheroids. We find that increased compressive stress leads to decreased drug efficacy. Theoretical modeling and experiments suggest that mechanical stress leads to decreased cell proliferation which in turn reduces the efficacy of chemotherapeutics that target proliferating cells. Our work highlights a mechanical-form of drug resistance, and suggests new strategies for therapy.

1 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
GCGiovanni Cappello
Giovanni Cappello
FWFanny Wodrascka
Fanny Wodrascka
GMGenesis Marquez-Vivas
Genesis Marquez-Vivas
ARAmr Eid Radwan
Amr Eid Radwan
PAParvathy Anoop
Parvathy Anoop
TBThomas Boudou
Thomas Boudou
Cell contraction and proliferation, matrix secretion and external mechanical forces induce compression during embryogenesis and tumor growth, which in turn regulate cell proliferation, metabolism or differentiation. How compression affects tissue contractility, a hallmark of tissue function, is however unknown. Here we apply osmotic compression to microtissues of either mouse colon adenocarcinoma CT26 cells, mouse NIH 3T3 fibroblasts, or human primary colon cancer-associated fibroblasts. Microtissues are anchored to flexible pillars that serve as force transducers. We observe that low-amplitude osmotic compression induces a rapid relaxation of tissue contractility, primed by the deformation of the extracellular matrix. Furthermore, we show that this compression-induced relaxation is independent of the cell type, proportional to the initial tissue contractility, and depends on RhoA-mediated myosin activity. Together, our results demonstrate that compressive stress can relax active tissue force, and points to a potential role of this feedback mechanism during morphogenetic events such as onco- or embryogenesis.

24 July 2025 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
OSOleksandr Sverdlov
Oleksandr Sverdlov
JRJone Renteria
Jone Renteria
KCKerstine Carter
Kerstine Carter
ASAnnika L Scheffold
Annika L Scheffold
JKJohannes Krisam
Johannes Krisam
JSJan Seidel
Jan Seidel
Background: There is emerging evidence of the increasing uptake of response-adaptive randomization (RAR) in clinical trials. However, a systematic review of RAR trials, their context of use, characteristics, and stakeholder acceptance has been lacking. Methods: We performed a systematic review of clinical trials that utilized elements of RAR, identified via the Cortellis Regulatory Intelligence database following a pre-specified selection process. We report a summary of relevant characteristics of the identified trials. Results: Out of 170 records, 39 RAR trials were identified (22 completed, 17 ongoing as of October 2024). The majority were Phase 2-focused studies (phases 1/2, 2, 2b, and 2/3), academically sponsored, and concentrated in oncology, neurology, and infectious diseases. Small molecules and biologics were the most common investigational products. Among the 22 completed trials, seven reported positive outcomes. Notably, two of these trials provided pivotal data that informed the further development and subsequent regulatory approval of the investigational compounds. Conclusion: Over the past two decades, RAR has been increasingly utilized in complex adaptive trials across diverse therapeutic areas and clinical research phases. This systematic review provides a critical “baseline” for tracing the dynamics of RAR applications and should help the clinical research community recognize RAR as a valuable methodology for optimizing future trial designs.

7 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
PMPietro Mascheroni
Pietro Mascheroni
SSSymeon Savvopoulos
Symeon Savvopoulos
JAJuan Carlos López Alfonso
Juan Carlos López Alfonso
MMMichael Meyer-Hermann
Michael Meyer-Hermann
Haralampos HatzikirouHaralampos Hatzikirou
Haralampos Hatzikirou
In clinical practice, a plethora of medical examinations are conducted to assess the state of a patient’s pathology producing a variety of clinical data. However, exploiting these data faces the following challenges: (C1) we lack the knowledge of the mechanisms involved in regulating these data variables, and (C2) data collection is sparse in time since it relies on patient’s clinical presentation. (C1) implies that only a small subset of the relevant variables can be modeled by virtue of mathematical modeling. This limitation allows models to be effective in analyzing the qualitative dynamics of the system, but limits their predictive accuracy. On the other hand, statistical learning methods are well-suited for quantitative reproduction of data, but they do not provide mechanistic understanding of the investigated problem. Moreover, due to (C2) any algorithm is challenged in learning the corresponding disease dynamics. Herein, we propose a novel method, based on the Bayesian coupling of mathematical modeling and machine learning (BaM 3 ), aiming at improving individualized predictions by addressing the aforementioned challenges. As a proof of concept, we evaluate the proposed method on a synthetic dataset for brain tumor growth and analyze its performance in predicting two major clinical outputs, namely tumor burden and infiltration. The BaM 3 method results in improved predictions in almost all simulated patients, especially for those with a late clinical presentation. In addition, we test the proposed methodology in two settings dealing with real patient cohorts. In both cases, namely cancer growth in chronic lymphocytic leukemia and ovarian cancer, BaM 3 predictions show excellent agreement with reported clinical data.